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gA nephropathy (IgAN), first described by Berger and Hinglais in 1968, 1 is the most common form of primary glomerulonephritis in the world. 2 Up to 40% of patients progress to end-stage renal disease within 20 years of diagnosis 3 because there is no disease-specific therapy. IgAN is a mesangioproliferative disease defined by the dominance or co-dominance of IgA in the mesangial immune deposits. IgA in the mesangial deposits is in the IgA1 subclass 4 and is enriched for IgA1, with some O-glycans being galactose-deficient (Gd-IgA1). 5, 6 IgAN has been characterized as an autoimmune disease, in which the IgA1-containing mesangial immunodeposits are likely derived from circulating immune complexes 7, 8 which consist of GdIgA1 (autoantigen) bound by Gd-IgA1Àspecific autoantibodies. [9] [10] [11] Patients with IgAN have elevated serum levels of Gd-IgA1 7, 10, [12] [13] [14] that are genetically codetermined. 15 Serum Gd-IgA1 levels predict disease progression, 16 presumably because they drive production of pathogenic immune complexes. 17, 18 Some circulating Gd-IgA1Àcontaining immune complexes deposit in the mesangium and then activate mesangial cells, thus initiating glomerular injury (for review, see Wyatt and Julian 8 and Mestecky et al. 19 ). Clinical expression of IgAN, particularly in children and adolescents, is often characterized by macroscopic hematuria associated with infections of the upper respiratory tract 20 and/or the digestive system. 21 It has therefore been proposed that the pathogenesis of IgAN may be related to abnormalities of the mucosal immune system, including the tonsils. 22, 23 Genome-wide association studies (GWAS) support these conclusions because several candidate loci contain genes involved in innate and mucosal immunity. 24, 25 It is speculated that levels of Gd-IgA1 in the circulation increase during mucosal infections. 26 These infections can have a substantial impact on cytokine production; for example, they result in elevated local and circulatory levels of interleukin-6 (IL-6) in IgAN patients that may subsequently affect IgA1 O-glycosylation. 26, 27 Studies of pathogenesis of IgAN are complicated by uniqueness of the human IgA system. This uniqueness prevents studies of IgA1 O-glycosylation in experimental animals because only humans and hominoid primates have IgA1 subclass with its O-glycans. To circumvent this problem, we generated immortalized IgA1-producing cell lines from IgAN patients and healthy control subjects (HCs) as a model system for analyses of IgA1 O-glycosylation pathways. 28 Our studies revealed that cells from patients with IgAN secrete more Gd-IgA1 than do the cells from HCs, concordantly with the serum levels of Gd-IgA1 of the corresponding donors. The basis for production of Gd-IgA1 is abnormal expression and activity of 2 glycosyltransferases: decreased for core 1 b1,3-galactosyltransferase (C1GalT1), which adds galactose to N-acetylgalactosamine (GalNAc), and elevated for a-N-acetylgalactosaminide a-2,6-sialyltransferase II (ST6GalNAc-II), which adds sialic acid to GalNAc. 28 Moreover, in cells from IgAN patients, but not HCs, IL-6 increased galactose deficiency of secreted IgA1, which was likely due to the altered expression and activity of C1GalT1 and ST6GalNAc-II enzymes. 26 No other tested cytokine exhibited such a striking specific effect on Gd-IgA1 production.
In this study, we sought to understand the mechanisms that regulate these abnormal responses to IL-6. We analyzed IL-6 signaling pathways using IgA1-producing cells derived from the peripheral blood of patients with IgAN and HCs. Furthermore, we generated IgA1-producing cell lines from the tonsils of patients with IgAN and individuals with obstructive sleep apnea (OSA), and we report limited exploratory experiments with these cells as supplementary data. Using kinomic approaches, siRNA knock-down, and specific protein-kinase inhibitors, we determined that abnormal IL-6 signaling through the JAK/STAT3 pathway in IgA1-producing cells was associated with elevated synthesis of Gd-IgA1 in cells from patients with IgAN. These data thus provided a mechanism that explained a cytokine-driven increased formation of immune complexes and disease exacerbation in IgAN patients during mucosal infections. Furthermore, the findings identified a potential target for disease-specific intervention of this chronic disease that would reduce production of the main autoantigen, Gd-IgA1.
MATERIALS AND METHODS

Study Design and Preparation of Epstein-Barr VirusÀImmortalized IgA1-Secreting Cells
The study was designed to investigate the signaling mechanisms responsible for the IL-6-induced increase of Gd-IgA1 in IgAN. Protocols for obtaining the blood samples and tonsillar tissue for isolation of cells were approved by Institutional Review Boards of the University of Alabama at Birmingham and Juntendo University, and the samples were obtained after written informed consent was obtained from the study subjects.
Blood samples were obtained by venipuncture from 5 patients with biopsy-proven IgAN and 5 HCs. 28 Tonsil samples were obtained from 2 other patients with biopsy-proven IgAN and 2 individuals with OSA who had undergone tonsillectomy in Juntendo University Hospital. Tonsillar tissue samples were immediately dissected into small pieces that were mechanically dissociated on a 100-mm cell strainer. 29, 30 Mononuclear cells from blood and tonsil tissues were isolated by the Ficoll-Hypaque density gradient, and the cell cultures were treated with cyclosporine and thereafter immortalized by infection with the EpsteinBarr virus (EBV).
28
IgA1-secreting cells derived from blood or tonsils were subcloned by limiting dilution. 28 Cells were grown in Roswell Park Memorial Institute medium 1640 supplemented with 20% fetal bovine serum, 100 U/ml of penicillin, and 0.1 mg/ml of streptomycin in a humidified carbon dioxide (5%) incubator at 37 C. Cell viability was assessed by using trypan blue exclusion.
Treatment of Cells With IL-6 and JAK-STAT Pathway Inhibitors
IgA1-secreting cells were plated at 1 Â 10 5 cells/well in 24-well plates, treated with IL-6 (40 ng/ml) in the presence of the STAT3 inhibitor, Stattic (Tocris Bio-or with JAK inhibitor AZD1480 (LC Laboratories, Woburn, MA) (for peripheral blood mononuclear cell
[PBMC]Àderived cells, 0-2 mM; for tonsil-derived cells, 0-300 nM). The cells were pre-incubated with inhibitor for 1 hour before addition of IL-6. Samples of culture medium were harvested after 5 days for analyses of total IgA1 and Gd-IgA1.
Determination of Total IgA1 Concentration
Total IgA1 was measured by enzyme-linked immunosorbent assay (ELISA). 28 Microplates coated with 0.1 mg/ well of goat IgG F(ab 0 ) 2 specific for human IgA (Jackson ImmunoResearch Inc., West Grove, PA) were blocked with 1% bovine serum albumin (BSA) in phosphatebuffered saline (PBS) with 0.05% Tween 20 (PBS-T), washed, and incubated with serially diluted samples of cell-culture supernatants from IgA-producing cells, in conjunction with a standardized serum (Bio-Rad, Hercules, CA) for IgA quantification. Bound IgA was detected after addition of biotinylated goat IgG F(ab 0 ) 2 specific for human IgA (Biosource, San Diego, CA), followed by horseradish perioxidase (HRP)Àconjugated Extravidin (Sigma, St. Louis, MO) and o-phenylenediamine dihydrochloride-hydrogen peroxide peroxidase substrate (Sigma). Optical densities were measured at 490 nm on an EL808 microplate reader (BioTek, Winooski, VT). As indicated previously, we cloned IgA-secreting cells and confirmed that the secreted IgA was exclusively IgA1; thus, we refer to it as total IgA1. 28 Gd-IgA1 Assay Gd-IgA1 secreted in culture medium was measured by lectin ELISA. 28 Microplates coated with 0.25 mg/well of goat IgG F(ab 0 ) 2 specific for human IgA (Jackson ImmunoResearch Inc.) were blocked with 1% BSA in PBS-T, washed, and incubated with cell-culture supernatant added at 100 ng of IgA1 per well, and incubated overnight at 4 C. Captured IgA1 was desialylated by neuraminidase (Arthrobacter ureafaciens; Glyko, Toronto, Ontario, Canada) at 2 mU/ml for 3 hours at 37 C. Gd-IgA1 was detected using biotinylated lectin from Helix aspersa (Sigma; HAA), specific for terminal GalNAc, at 2 mg/ml in 1% BSA in PBS-T, followed by HRP-conjugated Extravidin and o-phenylenediamine dihydrochloride-hydrogen peroxide peroxidase substrate. Optical densities were measured at 490 nm. The Gd-IgA1 concentration was determined by interpolating the sample optical density of the individual to the optical density on the standard curve constructed using serially diluted Gd-IgA1 (Ale). Because the standard Gd-IgA1 myeloma protein is not entirely devoid of galactose, the expression of results in micrograms per milliliter does not precisely reflect the concentration of Gd-IgA1 in the sera. Therefore, we expressed the results in units per milliliter. One unit of Gd-IgA1 was defined as 1 mg of this standard Gd-IgA1 myeloma protein.
Evaluation of Phosphorylation of STAT3
To evaluate STAT3 phosphorylation in individual cell lines treated with IL-6 and JAK-STAT inhibitors, cells were plated in 6-well plates at 1 Â 10 6 cells/well and treated with different concentrations of AZD1480 or Stattic for 1 hour, followed by addition of IL-6 at a final concentration of 40 ng/ml for 15 minutes. Cell lysates were prepared for Western blot analyses using M-PER lysis buffer with a cocktail of phosphatase and protease inhibitors (Thermo Fisher Scientific, Waltham, MA). To determine the long-term effects of IL-6 treatment on phosphorylation of STAT3, EBV-immortalized, IgA1-producing cell lines derived from cells in the peripheral blood of IgAN patients (IgAN-PB cells) and HC (HC-PB cells) were exposed to IL-6 at a final concentration of 40 ng/ml for 1, 3, and 48 hours in the presence or absence of JAK inhibitor AZD1480 (0.3-or 2-mM concentration).
Sodium DodecylsulfateÀPolyacrylamide Gel
Electrophoresis and Western Blot Analysis IL-6-and JAK-STATÀtreated cells were spun down, and the pellets were washed in ice-cold PBS and lysed in M-PER lysis buffer containing a protease inhibitor cocktail and a phosphatase inhibitor cocktail (Thermo Fisher Scientific). Cell debris was removed by centrifugation for 10 minutes at 14,000g at 4 C. Protein concentrations in the supernatants were measured using a protein assay kit (Bio-Rad); aliquots corresponding to 7 mg/lane of total protein were separated by sodium dodecylsulfateÀpolyacrylamide gel electrophoresis and transferred to polyvinylidene diflouride membrane for Western blot analysis. After transfer, the membranes were blocked by Superblock (Thermo Fisher Scientific) and incubated with phospho-Y705-STAT3-or phospho-S727-STAT3Àspecific rabbit polyclonal antibodies, both diluted 1:800 in blocking buffer, or with STAT3-specific mouse monoclonal antibodies diluted 1:10,000 (R & D Systems, Minneapolis, MN). Bound antibodies were detected by addition of HRP-conjugated anti-rabbit (1:4000) or anti-mouse (1:10,000) IgG antibodies (Southern Biotech, Birmingham, AL), respectively, followed by addition of chemiluminescence substrate (Thermo Fisher Scientific), then visualized on Kodak radiography film (Kodak, Rochester, NY). Densitometric evaluation with ImageJ software (National Institutes of Health, Bethesda, MD; https://imagej.nih.gov/ij/) was used with in vitro titration of STAT3 in cellular lysates for calibration of densitometric curves.
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Quantitative Real-Time Polymerase Chain Reaction Analysis RNA was isolated from 2 Â 10 5 cells using the RNeasy 96 Mini Kit (Qiagen, Hiden, Germany) and converted to cDNA by the SuperScript III First-Strand Synthesis SuperMix kit (Invitrogen, Carlsbad, CA). Levels of STAT3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcripts were determined by real-time polymerase chain reaction (RT-PCR) using LightCycler 480 DNA SYBR Green I Master chemistry on LightCycler 480 instrument (Roche, Basel, Switzerland). Results were expressed as the fold change versus the result for the corresponding GAPDH housekeeping gene mRNA values using the 2-DDCt method.
31
STAT3 siRNA Treatment IgA1-producing cell lines derived from PBMCs from 3 patients with IgAN (IgAN-PB) and 3 HC-PB were transfected by ON-TARGETplus SMARTpool siRNAs (Thermo Fisher Scientific) specific for human STAT3. ON-TARGETplus nontargeting SMARTpool siRNAs served as a control. Cells were inoculated at a density of 5 Â 10 5 /ml 24 hours before siRNAs were added. Before transfection, the cells were harvested by centrifugation for 10 minutes at 300g and resuspended at room temperature in Nucleofector Solution C (Lonza, Basel, Switzerland) at a density of 2.5 Â 10 6 /100 ml for each transfection. After addition of 1.4 mg of individual siRNA, cells were pulsed in an Amaxa nucleofector II (Lonza) using program X-001 and then immediately transferred to a 24-well panel containing 1.4 ml of culture medium and incubated in humidified carbon dioxide incubator at 37 C. Twenty-four hours after transfection, the knock-down efficiency was determined by RT-PCR. The knock-down effect was expressed as cDNA level of the individual gene normalized to GAPDH, after respective siRNA treatment, divided by respective value obtained after treatment by nontargeting siRNA.
Kinomic Profiling
Cell lysates from IgAN-PB and HC-PB cells (n ¼ 3 for each) stimulated with 40 ng/ml of IL-6 were incubated without or with 1 mM AZD1480 for 10 minutes immediately before kinomic analysis using high-throughput phosphopeptide microarrays. All analyses were performed in triplicate. Kinomic profiling was performed on cell lysates obtained by lysing 5 Â 10 5 cells with M-PER lysis buffer as described in the section on Western Blotting Analysis and using the PamStation 12 platform (PamGene, 's-Hertogenbosch, Netherlands) in the UAB Kinome Core (www.kinomecore.com). [32] [33] [34] After protein quantification by the bicinchoninic acid method (Thermo Fisher Scientific), lysates (12.5 mg protein)
were loaded in kinase reaction buffer onto the TyrosineKinase PamChip (PamGene). This platform uses a high-throughput peptide microarray system analyzing 144 individual tyrosine phosphorylatable peptides imprinted and immobilized in a 3-dimensional format to assess kinomic activity in cell lysates. Fluorescein isothiocyanateÀconjugated anti-phosphotyrosine antibodies were used for visualization. Kinomic profiling data were analyzed using Evolve microarray software (PamGene). BioNavigator software (PamGene) was used for raw data transformation into kinetic (initial velocity) and steady-state (postwash) values across multiple exposure times. Significantly altered peptide lists (unpaired Student's t-test) were generated and uploaded to GeneGo MetaCore (portal.genego.com; Thompson Reuters, New York, NY) for network analysis, performed on September 5, 2012. Significantly altered peptide lists were cross compared for recurrent upstream kinases in Kinexus kinase predictor (www.phosphonet.ca), and scored according to recurrence and percent occurrence, as in our reports. 33, 34 Statistical Analyses Results were expressed as mean AE SD (in some graphs, data are shown as means þ SD for clarity). Data were analyzed using 2-tailed Student's t-test (unpaired or paired, as applicable). For analyzing multiple groups, 1-way analysis of variance was used, and P < 0.05 was regarded as significant. 
RESULTS
IL-6 Increases
IL-6 Signaling Increases STAT3 Phosphorylation in IgA1-Secreting Cells of Patients With IgAN and HCs
In a pilot experiment performed with EBVimmortalized, IgA1-producing cell lines derived from PBMC from an IgAN patient and a HC, we tested whether the canonical STAT3 pathway was activated by IL-6. We found that IL-6 induced STAT3 phosphorylation at Y705, the STAT3 phospho-activation site, but not at S727 (the other site for transcriptional activation in STAT3) (Figure 2a-c) . STAT3 phosphorylation at Y705 peaked at 15 minutes and was more pronounced in IgAN-PB cells than in HC-PB cells (Figure 2a and b) . To confirm this difference for the phosphorylation at Y705, the experiment was repeated using IgA1-producing cell lines from 3 IgAN patients and 3 HCs. STAT3 phosphorylation at Y705 with IL-6 stimulation for 15 minutes was greater for the IgAN cell lines (Figure 2d and e). mRNA expression of the genes encoding the IL-6 receptor (IL-6R1, 2, and 3) in IgAN-PB and HC-PB cells did not reveal any significant differences. IL-6 stimulation did not alter mRNA levels of IL-6R1, 2, and 3 in IgA1-producing cell lines (data not shown). (Figure 3a) . STAT3 protein levels were reduced in STAT3 siRNA-treated cells by >80% for both groups of cell lines (Figure 3b and c) . Furthermore, the IL-6Àinduced increase in production of GdIgA1 in IgAN-PB cells was reduced by STAT3 siRNA knock-down (Figure 3d ). STAT3 siRNA knock-down was associated with reduced total STAT3 protein and its phosphorylation at Y705 (Supplementary Figure S2a) . IL-6Àinduced production of IgA1 in IgAN-PB cells was not altered by STAT3 siRNA knockdown (Supplementary Figure S2b) . 
IL-6 Induced Long-Lasting STAT3 Phosphorylation in IgAN-PB Cells; AZD1480 Inhibited This Effect
The IL-6-induced STAT3 phosphorylation at Y705 in IgAN-PB cells started to weaken after 1 hour, but was detected even after 48 hours (Figure 6a and b) . In contrast, for HC-PB cells, this IL-6Àinduced phosphorylation was not long-lasting, and had dissipated by 3 hours (Figure 6a and b) .
Kinomic Profiling Confirmed STAT-Signaling Pathways as the Main Target of AZD1480
Reducing the IL-6ÀMediated Gd-IgA1 Overproduction Kinomic profiling of IL-6Àstimulated PBMC-derived cells from patients with IgAN versus those from HCs identified signaling pathways that were differentially inhibited by AZD1480. The cell lysates were treated ex vivo for 10 minutes with the inhibitor before the Table S1 ). The JAK/STAT signaling pathway was previously identified as one of the top pathways enriched among the GWAS signals for IgAN (enrichment P ¼ 6.7 Â 10 À14 ) 25 . Thus, our kinomic profiling results provided orthogonal evidence for the involvement of this pathway in the pathogenesis of IgAN.
DISCUSSION
The frequent occurrence of macroscopic hematuria during upper respiratory tract infections in IgAN patients suggests a connection between mucosal inflammation and kidney damage in these patients. 17, 22, 35 In support of this connection, most GdIgA1 in circulating immune complexes is a polymeric form that is typically produced only at mucosal sites, 36 whereas most circulatory IgA1 is predominantly monomeric and produced in the bone marrow. Therefore, there is a possible connection between mucosal inflammation and increased synthesis of circulatory polymeric IgA1. There is limited information on the origin of Gd-IgA1Àproducing cells, but IgAN is now well characterized by the galactose deficiency of the IgA1 in the mesangial immunodeposits. This deposited Gd-IgA1 is likely derived from circulating immune complexes formed from Gd-IgA1 bound by GdIgA1Àspecific autoantibodies.
9-11 Serum IgA1 in healthy individuals is believed to contain few or no galactose-deficient O-glycans, in contrast to that in IgAN patients. 7, 10, [12] [13] [14] 37 Why Gd-IgA1 is primarily in the polymeric form is unknown, whether as a byproduct of aberrant glycosylation itself or due to the mechanisms driving its production. Further investigation into the origin of Gd-IgA1Àproducing cells may provide insights about environmental factors that affect aberrant glycosylation and may elucidate the connection between mucosal inflammation and kidney damage in IgAN patients. However, these studies are hampered by the lack of suitable experimental animal models, because only humans and hominoid primates have IgA1 with its O-glycans. Thus, alternative approaches must be used, such as IgA1-producing cells derived from the blood or tonsils of patients with IgAN and control subjects. Elevated levels of circulatory Gd-IgA1 or GdIgA1Àcontaining immune complexes in patients with IgAN have been correlated to disease progression or activity. 16, 17 This study showed how IL-6 mediates a significant effect on IgA1 glycosylation in cells of IgAN patients, but not in healthy individuals. IL-6 production is typically associated with activated, cytokine-producing, T cells. 38 Thus, T cells have been implicated as a source of cytokines during mucosal infections, and as a contributor to the pathogenesis of IgAN. [39] [40] [41] [42] In addition, Th2 cytokine IL-4 may also play a role in controlling O-glycosylation of the IgA1 hinge region. 43 Although IL-4 did not elicit as much of an increase in Gd-IgA1 production from cells from IgAN patients as did IL-6, it is clear that O-glycosylation varies depending, in part, on the local cytokine milieu. 26, 27, 43, 44 Increased production of cytokines, such as IL-6, during mucosal inflammation may potentially explain clinical flares in IgAN patients that frequently coincide with common respiratory or gastrointestinal infections.
Across several ethnic backgrounds, serum Gd-IgA1 levels are a heritable trait. 15, 45, 46 Asymptomatic blood relatives of IgAN patients frequently have significantly higher levels of Gd-IgA1 than do unrelated HCs, indicating that this abnormality is a necessary but not sufficient condition for development of IgAN. 15, 46 GWAS data support a genetic component, and recent reports have suggested that some stimuli, on a permissive genetic background, may cause low gene expression of C1GALT1 and COSMC, but enhanced gene expression of ST6GALNAC-II. 28, 47, 48 The result of these 3 effects is reduced C1GalT1 activity and a lower content of galactose in the circulatory IgA1 in IgAN patients. The IL-6Àenhanced aberrant glycosylation of IgA1 involves further dysregulation of expression and activity of C1GalT1 and ST6GalNAc-II in the cells from IgAN patients, leading to greater production of Gd-IgA1. 26 The association of C1GALT1 and COSMC alleles with serum levels of Gd-IgA1 was revealed in a recent GWAS that confirmed the role of C1GalT1 in the production of Gd-IgA1. 49 Moreover, patients with IgAN have elevated levels of IL-6 in the circulation and locally in the kidneys. [50] [51] [52] IL-6 might play a crucial role in the pathogenesis of certain autoimmune and inflammatory diseases. 53 GWAS revealed a strong association of the genomic locus that encodes leukemia inhibitory factor and oncostatin M, 2 cytokines from the IL-6 family involved in mucosal immunity, with the risk of IgAN 25, 54 and inflammatory bowel disease. 55, 56 Differential activities of cytokines between patient and control cells highlighted either a change in signaling properties upstream or regulation of transcriptional activity downstream in controlling the glycosylation of Figure 7 . Kinomic profiling of IgA1-secreting cells from healthy control subjects (HC) and IgA nephropathy (IgAN) patients stimulated with interleukin-6 (IL-6) with or without the AZD1480 inhibitor. Direct interaction mapping using GeneGo MetaCore of phosphopeptides that were significantly inhibited by AZD1480-treated lysate from IgA1-secreting cells derived from peripheral blood mononuclear cells from patients with IgAN but not those from HCs, after IL-6 stimulation. In addition, a Build a Network modeling tool was used to generate likely interactions that link uploaded objects (significant phosphopeptides inhibited in the cell lysate from IgAN patients) similar to the known pathway models. Pathways representing vascular endothelial growth factor receptor (VEGFR) and STAT signaling axes were found and are displayed as the networks Signal transduction VEGF, STAT3 signaling (red circles).
IgA1. Consequently, multiple approaches are being developed and tested for therapeutic blocking of IL-6 activity. 57, 58 We focused on the signaling mechanisms responsible for an IL-6Àmediated increase in Gd-IgA1 production. We used IgA1-secreting cells derived from cells in peripheral blood and tonsils of patients with IgAN and control subjects without kidney disease. STAT3 phosphorylation is the classical signaling pathway associated with IL-6 signaling; therefore, we extended the approaches of other studies to analyze the level of STAT3 activation after IL-6 stimulation. [59] [60] [61] The activation of STAT signaling pathways requires tyrosine phosphorylation of STAT proteins. 62 In our study, IL-6 activation of STAT3 phosphorylation (Y705) was greater and persisted longer in IgA1-producing cells from IgAN patients compared with those from control subjects. The IL-6Àinduced increases in Gd-IgA1 production by IgA1-producing cells from IgAN patients were significantly reduced after siRNA STAT3 knock-down. Small molecule inhibitors of the JAK/ STAT3 pathway had varied efficacies in blocking IL6Àinduced production of IgA1 in cells from IgAN patients and the control subjects, and in reducing production of Gd-IgA1 in IgAN cells. Kinomic analysis of tyrosine activation further validated the differential regulation of STAT3 signaling in IgAN cells compared with control cells. In addition, IgA1-producing, tonsilderived cells from IgAN patients showed similarly enhanced Gd-IgA1 production and STAT3 activation in response to IL-6, which indicated the ubiquitous nature of dysregulated glycosylation of IgA1 in IgAN.
We analyzed 9 different STAT3 ChIP-seq datasets for B cells, to search for STAT3-binding sites close to any of the key glycosyltransferase genes involved in Gd-IgA1 production. We found upstream and downstream binding-site hits for the C1GALT1 gene, which provided further insight into possible control of this gene mediated by IL-6/STAT3 signaling. Specifically, because the binding sites for transcription factor SP1/3 at the promoter of C1GALT1 gene play an essential role in transcriptional regulation, 63 one can envision a negative regulatory effect by activated STAT3. This model would explain the previously observed downregulation of C1GALT1 transcription after IL-6 stimulation.
26
STAT3 signaling is a critical interface between autoimmunity and immune deficiency. Dominant negative mutations produce an immunodeficiency syndrome that results in hyper-IgE production, recurrent staphylococcal infections, and eczema, attributed to impaired IL-17 signaling in this disorder. 64, 65 Gain-in-function mutations in STAT3 produce autoimmunity with a high predisposition to type 1 diabetes, celiac disease, and hematologic disorders. [66] [67] [68] [69] In these conditions and other diseases, treatment aimed at abnormal STAT3 signaling greatly ameliorated the symptoms. 70, 71 In summary, an enhanced and extended IL6Àinduced activation of STAT3 phosphorylation (Y705) represents a pathogenic process in IgAN that results in the overproduction of Gd-IgA1, the key pathogenic molecule in IgAN. Because there is no targeted therapy of IgAN, IL-6Àmediated STAT3 signaling offers a promising area for investigation for treatment of this disease.
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